Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation

Schernberg, Antoine; Nivet, A.; Dhermain, Frédéric; Ammari, Samy; Escande, Alexandre; Pallud, Johan; Louvel, G.; Deutsch, Éric

doi:10.1016/j.ctro.2018.04.002

Cited by 37 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, others have shown that patients with neutrophilia prior to treatment have worse outcomes after radiation therapy in multiple cancer types (18). In patients with high-grade gliomas treated with concurrent temozolomide and radiation, pretreatment neutrophilia was a significant prognostic factor for poor overall survival (57).…”

Section: Discussionmentioning

confidence: 99%

Neutrophils promote tumor resistance to radiation therapy

Wisdom

Hong

Lin

et al. 2019

Proc. Natl. Acad. Sci. U.S.A.

108

View full text Add to dashboard Cite

Nearly two-thirds of cancer patients are treated with radiation therapy (RT), often with the intent to achieve complete and permanent tumor regression (local control). RT is the primary treatment modality used to achieve local control for many malignancies, including locally advanced cervical cancer, head and neck cancer, and lung cancer. The addition of concurrent platinum-based radiosensitizing chemotherapy improves local control and patient survival. Enhanced outcomes with concurrent chemoradiotherapy may result from increased direct killing of tumor cells and effects on nontumor cell populations. Many patients treated with concurrent chemoradiotherapy exhibit a decline in neutrophil count, but the effects of neutrophils on radiation therapy are controversial. To investigate the clinical significance of neutrophils in the response to RT, we examined patient outcomes and circulating neutrophil counts in cervical cancer patients treated with definitive chemoradiation. Although pretreatment neutrophil count did not correlate with outcome, lower absolute neutrophil count after starting concurrent chemoradiotherapy was associated with higher rates of local control, metastasis-free survival, and overall survival. To define the role of neutrophils in tumor response to RT, we used genetic and pharmacological approaches to deplete neutrophils in an autochthonous mouse model of soft tissue sarcoma. Neutrophil depletion prior to image-guided focal irradiation improved tumor response to RT. Our results indicate that neutrophils promote resistance to radiation therapy. The efficacy of chemoradiotherapy may depend on the impact of treatment on peripheral neutrophil count, which has the potential to serve as an inexpensive and widely available biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutrophils promote tumor resistance to radiation therapy

Wisdom

Hong

Lin

et al. 2019

Proc. Natl. Acad. Sci. U.S.A.

108

View full text Add to dashboard Cite

show abstract

“…In addition, Schernberg et al reported that pretreatment neutrophilia is negatively associated with overall survival in GBM patients who undergo concurrent treatment with TMZ and RT [43]. Baseline circulatory neutrophil count predicts bevacizumab efficacy in GBM patients, although the role of neutrophils in the antitumor response of anti-VEGF therapy is unclear [44].…”

Section: Circulating Neutrophils In Glioma Progression and Treatment mentioning

confidence: 99%

Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance

Khan

Mittal

McGee

et al. 2020

IJMS

View full text Add to dashboard Cite

Recent efforts in brain tumor research have been directed towards the modulation of the immune system for therapeutic interventions. Several human cancers, including gliomas, are infiltrated with immune cell types—including neutrophils and myeloid-derived suppressor cells—that contribute to tumor progression, invasiveness, and treatment resistance. The role of tumor-associated neutrophils and myeloid-derived suppressor cells in cancer biology remains elusive, as these cells can exert a multitude of pro-tumor and antitumor effects. In this review, we provide the current understanding and novel insights on the role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance, as well as the mechanisms of pleiotropic behaviors in these cells during disease progression, with an emphasis on possible strategies to reprogram these cells towards their antitumor actions.

show abstract

“…Neutrophils systemically and intratumorally accumulate in glioma patients and a high frequency of neutrophils is negatively associated with the prognosis of GBM patients [ 123 , 124 , 125 , 126 ] ( Figure 1 ). Moreover, the number of tumor infiltrating neutrophils correlates with glioma grade and represents a negative prognostic parameter for resistant patients [ 127 , 128 ].…”

Section: Neutrophils In Gbmmentioning

confidence: 99%

Myeloid Cells in Glioblastoma Microenvironment

Leo

Ugolini

Veglia

2020

Cells

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is notoriously resistant to immunotherapy mainly due to its unique immune microenvironment. High dimensional data analysis reveals the extensive heterogeneity of immune components making up the GBM microenvironment. Myeloid cells are the most predominant contributors to the GBM microenvironment; these cells are critical regulators of immune and therapeutic responses to GBM. Here, we will review the most recent advances on the characteristics and functions of different populations of myeloid cells in GBM, including bone marrow-derived macrophages, microglia, myeloid-derived suppressor cells, dendritic cells, and neutrophils. Epigenetic, metabolic, and phenotypic peculiarities of microglia and bone marrow-derived macrophages will also be assessed. The final goal of this review will be to provide new insights into novel therapeutic approaches for specific targeting of myeloid cells to improve the efficacy of current treatments in GBM patients.

show abstract

Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation

Cited by 37 publications

References 28 publications

Neutrophils promote tumor resistance to radiation therapy

Neutrophils promote tumor resistance to radiation therapy

Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance

Myeloid Cells in Glioblastoma Microenvironment

Contact Info

Product

Resources

About